Treatment of Neuroblastoma by 131I-Metaiodobenzylguanidine (131I-MIBG): Qualitative and Quantitative Scintigraphic Evaluation of the Treatment Effect

Happ, J.; Griese, Janine; Maul, F. D.; Baüm, Richard; Manegold, Karl-Heinz; Gerein, V.; Schwabe, Dirk; Klinter, D.; Szepesi, S.; Kornhuber, B.; G, Hör

doi:10.1007/978-3-642-70947-0_48

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response appeared to correlate with the growth rate and localization of the tumor and with the absorbed radiation dose. Since then I 131-MIBG therapy has been attempted in several centers for neuroblastoma and a few other neural crest tumors [3-51. Happ et al [6], evaluating the scintigraphic treatment effects in neuroblastoma patients quantitatively, favors the concept that stage IV or inoperable neuroblastoma cases be treated with I 131-MIBG in an earlier phase, when the tumor is still well differentiated, and that for this purpose a few courses of high doses of I 131-MIBG are more adequate than multiple low doses.…”

Section: Introductionmentioning

confidence: 99%

Radionuclide therapy of neural crest tumors

Voûte

Hoefnagel

Kraker

et al. 1987

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

The potential concentration of I 131-Meta-iodo-benzylguanidine (MIBG) in pheochromocytoma, and the successful application in diagnosis and therapy of pheochromocytoma, has led to its use in therapy in other tumours derived from the neural crest. In neuroblastoma, the concentration of MIBG is as reliable as it is in pheochromocytoma. 18 patients with a neuroblastoma were treated, leading to two complete remissions, seven partial remissions, two no change, and two progressive disease; one patient was lost for follow-up. Six adults were treated, three with a carcinoid, two malignant pheochromocytoma and one medullary thyroid carcinoma. Although follow-up is still short, preliminary results of therapeutic use of I 131-MIBG indicate that this treatment modality may be effective.

show abstract

Section: Introductionmentioning

confidence: 99%

Radionuclide therapy of neural crest tumors

Voûte

Hoefnagel

Kraker

et al. 1987

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

Treatment of neuroblastoma with ¹³¹I‐metaiodobenzylguanidine

Troncone

Riccardi

Montemaggi

et al. 1987

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity 131I-metaiodobenzylguanidine (131I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an approach never previously reported. Single doses of 131I-MIBG varying from 70 to 184 mCi split into two parts were administered by slow i.v. infusion (4 to 8 hours) at 2- to 4-day intervals. The following results were obtained in the six evaluable patients: two patients showed transient stabilization of the disease; three had an objective response, with shrinking of the primary tumor and/or regression of the metastatic lesions. Of these three patients, two suffered relapses at 2 and 7 months, respectively, from the first course of MIBG. The third patient, in whom the residual disease almost completely disappeared following MIBG therapy, is still alive in complete remission after autologous bone marrow transplantation with a follow-up of 14 months. The single patient treated at diagnosis showed a dramatic response to a relatively low dosage of MIBG, with histologically proved disappearance of the tumor mass. Our data indicate that MIBG may be useful in the treatment of neuroblastoma unresponsive to conventional chemotherapy. The complete response observed in the patient treated at diagnosis suggests that the full potentiality of MIBG therapy should be explored in untreated patients.

show abstract

Treatment of Neuroblastoma by 131I-Metaiodobenzylguanidine (131I-MIBG): Qualitative and Quantitative Scintigraphic Evaluation of the Treatment Effect

Cited by 2 publications

References 2 publications

Radionuclide therapy of neural crest tumors

Radionuclide therapy of neural crest tumors

Treatment of neuroblastoma with ¹³¹I‐metaiodobenzylguanidine

Contact Info

Product

Resources

About

Treatment of Neuroblastoma by 131I-Metaiodobenzylguanidine (131I-MIBG): Qualitative and Quantitative Scintigraphic Evaluation of the Treatment Effect

Cited by 2 publications

References 2 publications

Radionuclide therapy of neural crest tumors

Radionuclide therapy of neural crest tumors

Treatment of neuroblastoma with 131I‐metaiodobenzylguanidine

Contact Info

Product

Resources

About

Treatment of neuroblastoma with ¹³¹I‐metaiodobenzylguanidine